grant
Project 2: Intratumoral PDT Induces PDP-based Enhancement of PD-1 Inhibition in Pancreatic Carcinoma
Organization MASSACHUSETTS GENERAL HOSPITALLocation BOSTON, UNITED STATESPosted 1 Dec 1999Deadline 29 Feb 2028
NIHUS FederalResearch GrantFY2026Abscopal effectAdverse ExperienceAdverse eventAreaB7-H1BPD verteporfinBPD-MABasal Cell CancerBenzoporphyrin Derivative Monoacid Ring ABiological MarkersBlood VesselsBuccal MucosaCAT scanCD274CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCT X RayCT XrayCT imagingCT scanCTCAECancer PatientCancersCell BodyCell Communication and SignalingCell SignalingCellsCessation of lifeCharacteristicsCheckpoint inhibitorClinicClinicalCombined Modality TherapyCommon Terminology Criteria for Adverse EventsCommon Toxicity CriteriaComputed TomographyDeathDetectable Residual DiseaseDevelopmentDiseaseDisorderDistant CancerDistant MetastasisDrugsEndoscopic UltrasonographyEpidermoid Cell CancerExocrine Pancreas CarcinomaFNAFine Needle AspirateFine needle aspiration biopsyFine-Needle AspirationFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFluorescenceGoalsGranzymeHourIV bolusImageImmuneImmune checkpoint inhibitorImmune mediated therapyImmune responseImmune systemImmunesImmunologic StimulationImmunological StimulationImmunologically Directed TherapyImmunostimulationImmunotherapyInflammatory InfiltrateIntracellular Communication and SignalingIntravenousIntravenous BolusKeytrudaLeftLightLondonLongitudinal CTLymph Node Reticuloendothelial SystemLymph Node TissueLymph node properLymphatic cellLymphatic nodesLymphocyteLymphocyte SubpopulationsLymphocyte SubsetLymphocyticMalignant Epidermoid Cell NeoplasmMalignant Epidermoid Cell TumorMalignant MelanomaMalignant NeoplasmsMalignant Pancreatic NeoplasmMalignant Skin NeoplasmMalignant Squamous Cell NeoplasmMalignant Squamous Cell TumorMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMalignant neoplasm of pancreasMeasurementMedicationMelanomaMetastasisMetastasis to the LungMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Neoplasm to the LungMetastatic TumorMetastatic Tumor to the LungMiceMice MammalsMicrosatellite InstabilityMinimal Residual DiseaseMolecularMonitorMouth MucosaMultimodal TherapyMultimodal TreatmentMurineMusNecrosisNecrosis InductionNecroticNeedlesNeoplasm MetastasisOral MucosaOral mucous membrane structureOutcomePBMCPD 1PD-1PD-L1PD1PDL-1PUVAPUVA PhotochemotherapyPancreas CancerPancreas Ductal AdenocarcinomaPancreas NeoplasmsPancreas TumorPancreatic CancerPancreatic Ductal AdenocarcinomaPancreatic TumorPancreatic carcinomaPatientsPatternPerfusionPerioperativePeripheralPeripheral Blood LymphocytePeripheral Blood Mononuclear CellPharmaceutical PreparationsPhase 2 Clinical TrialsPhase II Clinical TrialsPhotochemotherapyPhotodynamic TherapyPhotoradiationPhotosensitizersPhotosensitizing AgentsPopulationPrimary LesionPrimary NeoplasmPrimary TumorProcessProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1Progression-Free SurvivalsPulmonary CancerPulmonary malignant NeoplasmQuality of Life AssessmentRecurrent Malignant NeoplasmRecurrent Malignant TumorRegulatory T-LymphocyteRepeated CTResearchResidual NeoplasmResidual TumorsResistanceSamplingSecondary NeoplasmSecondary TumorSequential CTSignal TransductionSignal Transduction SystemsSignalingSkin CancerSkin NeoplasmsSkin TumorSquamous Cell CancersT-Cell ActivationT-CellsT-LymphocyteT8 CellsT8 LymphocytesTherapeuticTomodensitometryToxic effectToxicitiesTregUniversitiesVerteporfinVisudyneWorkX-Ray CAT ScanX-Ray Computed TomographyX-Ray Computerized TomographyXray CAT scanXray Computed TomographyXray computerized tomographyabscopal activityabscopal responseactivate T cellsadvanced pancreatic canceraspiratebenzoporphyrin Dbio-markersbiologic markerbiological signal transductionbiomarkercancer metastasiscancer progressioncancer recurrencecatscancheck point blockadecheckpoint blockadechemotherapyclinical outcome assessmentcollegecollegiatecombination therapycombined modality treatmentcombined treatmentcomputed axial tomographycomputer tomographycomputerized axial tomographycomputerized tomographycytotoxicdevelopmentaldosimetrydrug/agentendomicroscopyendoscopic ultrasoundflow cytophotometryhost responseimage guidanceimage guidedimagingimmune check point blockadeimmune check point inhibitorimmune checkpoint blockadeimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoresponseimprovedin vivoindexinglung cancerlung metastasislymph celllymph glandlymph nodeslymphnodesmalignancymalignant skin tumormetastasize to the lungmicroendoscopymulti-modal therapymulti-modal treatmentneoplasm progressionneoplasm/cancerneoplasm/cancer photoradiation therapyneoplastic progressionnon-contrast CTnoncontrast CTnoncontrast computed tomographyoptical fiberoral mucosaeoral mucosalpancreas carcinomapancreatic cancer modelpancreatic cancer patientspancreatic malignancypancreatic neoplasiapancreatic neoplasmpancreatic tumor modelpatients with pancreatic cancerpembrolizumabperipheral bloodphase 2 studyphase II protocolphase II studyphotosensitizerpredict responsivenesspredicting responseprogrammed cell death 1programmed cell death ligand 1programmed cell death protein 1programmed cell death protein ligand 1programmed death 1protein death-ligand 1pulmonary metastasisradiomicsrecruitregulatory T-cellsrepeated computed tomographyresidual diseaseresistantresponseserial CTserial computed tomographyserial diagnostic computed tomographysle2systemic lupus erythematosus susceptibility 2thymus derived lymphocytetumortumor cell metastasistumor progressionvascularverteporphin
Description preview
ABSTRACT - Project 2
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies and typically presents at
advanced stages. Progress in treating these cancers has been slow and has produced only very modest
increases in survival. One of the few positive developments has been the use of immune checkpoint inhibitors
(ICI) in the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click